1383P Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA)

R Reisinger,U Swami,E.J Hernandez,N Sayegh,S Wesolowski,L Kiedrowski,P.M Coelho Barata,R Nussenzveig,G Lemmon,M.A Bilen,E Heath,L Nandagopal,H Babiker,S.K Pal,M.B Lilly,B.L Maughan,M Yandell,O Sartor,N Agarwal

doi:10.1016/j.annonc.2022.07.1515

1383P Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA)

R Reisinger, U Swami + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1515

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Huntsman Cancer Institute, University of Utah, Guardant (United States), Tulane University, Emory University, Karmanos Cancer Institute, University of Alabama at Birmingham, Mayo Clinic, City of Hope, University of South Carolina

#Comprehensive Genomic Profiling #Prostate Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differential sensitivity to PARP inhibitors may be explained by distinct genomic landscapes of BRCA1 versus BRCA2 co-segregating genes.

Full Text